

**INFORMATION DISCLOSURE CITATION**

Form PTO-1449 (Modified)

(Use several sheets if necessary)

ATTY. DOCKET NO.

IRVN-005CIP

SERIAL NO.

09/771,263

APPLICANT

Thompson et al.

FILING DATE

January 26, 2001

GROUP

Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
CY	AA	4,038,145	07/26/77	Devlin			
	AB	4,677,056	06/30/87	Dupont et al.			
	AC	4,716,111	12/29/87	Osband et al.			
	AD	5,057,423	10/15/91	Hiserodt et al.			
	AE	5,192,537	03/09/93	Osband			
	AF	5,308,626	05/03/94	Landucci et al.			
	AG	5,382,427	01/17/95	Plunkett et al.			
	AH	5,476,993	12/19/95	Richmond			
	AI	5,484,596	01/16/96	Hanna Jr. et al.			
	AJ	5,569,585	10/29/96	Goodwin et al.			
	AK	5,602,305	02/11/97	Pober et al.			
	AL	5,663,481	09/02/97	Gallinger et al.			
↓	AM	5,837,233	11/17/98	Granger			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
CY	AN	WO 91/01760	02/21/91	PCT			Yes No
	AO	WO 95/16775	06/22/95	PCT			
	AP	WO 95/20649	08/03/95	PCT			
	AQ	WO 95/31107	11/23/95	PCT			
	AR	WO 96/05866	02/29/96	PCT			
↓	AS	WO 96/07433	03/14/96	PCT			

EXAMINER	<i>Chris S L Hy</i>	DATE CONSIDERED	<i>5/28/02</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>Use several sheets if necessary</i>				ATTY. DOCKET NO. IRVN-005CIP	SERIAL NO. 09/771,263
				APPLICANT Thompson et al.	
				FILING DATE January 26, 2001	GROUP Unassigned

CY	AT	WO 96/29394	09/26/96	PCT				
	AU	WO 98/04282	02/05/98	PCT				
	AV	WO 98/16238	04/23/98	PCT				
	AW	1,297,002	03/10/92	Canada				
	AX	379 554 B1	05/15/96	Europe				ARR 04 2001
	AY	0 493 468 B1	04/17/96	Europe				
	AZ	EP 0 645 147	03/29/95	Europe				

RECEIVED

OTHER ART (*Including Author, Title, Date, Pertinent Pages, Etc.*)

CY	BA	Albright et al., (1977) "Immunogenetic control of brain tumor growth in rats" Cancer Research 22:2512-2521.
	BB	Animal Cell Culture: A Practical Approach, R.I. Freshney, ed., (1987) IRL Press, Oxford, Table of Contents, pp. vii-xii.
	BC	Appendix A: Curriculum vitae of Gale A. Granger
	BD	Appendix B (item 1): E.W.B. Jeffes et al. (1993) "Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated ILR2 stimulated killer (MAK) lymphocytes . . ." J. Neuro-Oncol. 15:141-155.
	BE	Appendix B (item 2): R.S. Yamamoto et al. "Basical and clinical studies with intratumor immonotherapy of gliomas with alloimmune lymphoid cells." Poster presentation, American Association of Neurological Surgeons.
	BF	Appendix B (item 3): G. Ioli et al. (1994) "Basic & clinical studies with intratumor immunotherapy of gliomas with allogeneic lymphoid cells" Proc. Amer. Assoc. Cancer Res. 35:518 (Abstract 3088).
	BG	Appendix B (item 4): G. Granger et al. (1995) "Basic and clinical studies of intralesional therapy of gliomas with allogeneic lymphoid cells" Proc. Amer. Assoc. Cancer Res. 36:472 (Abstract 2812).
	BH	Appendix C: Letters regarding Gifts from Good Samaritan Hospital to support research of Gale A. Granger; Table of Gifts
	BI	Appendix D: List of patients treated according to the invention up to September 26, 1996
	BJ	Appendix E: Break-down of charges for alloactivated donor cells produced at U.C.I.
	BK	Appendix F: Curriculum vitae of John C. Hiserodt
	BL	Appendix G: "Immunotherapy for recurrent high grade gliomas: I. A pilot study using intratumoral implants of MLC-activated allogeneic lymphoid cells for the treatment of recurrent malignant astrocytomas" by J.C. Hiserodt, S. Jacques, C. Dumas, and G.A. Granger. [Unpublished manuscript]

EXAMINER	<i>Chris L H Y</i>	DATE CONSIDERED	<i>5/28/02</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO.	SERIAL NO.
		IRVN-005CIP	09/771,263
		APPLICANT	
		Thompson et al.	
FILING DATE	GROUP		
January 26, 2001	Unassigned		
BM	Appendix H: Chart of data from brain cancer patients compiled in 1995		
BN	Appendix I: Data from treated brain cancer patients [compiled for submission to FDA]		
BO	Barba et al., (1989) "Intratumoral LAK cell and interleukin-2 therapy of human gliomas" J. Neurosurg. 70:175-182.		
BP	Bellgrau, (1983) "Induction of cytotoxic T Cell precursors in vivo" J. Exp. Med. HZ: 1505-1515.		
BQ	Berd et al. (1990) "Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients." J. Clin. Oncol. Vol. 8, 1858-1867		
BR	Burris et al., (1997) "Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil." Eur. J. Cancer 33:S18-22		
BS	Burris et al. (1997) "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer A randomized trial." J. Clin. Oncol. 15:2403-13.		
BT	Carmichael et al., (1996) "Phase 11 study of gemcitabine in patients with advanced pancreatic cancer." Br. J. Cancer 73:101-5		
BU	Carmichael, (1997) "Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine." Digestion 58:503-7		
BV	Carpinito, et al., (1985) "Effective Treatment of Metastatic Carcinoma with In Vitro Immunized Autologous Lymphocytes and Cimetidine," The Journal of Urology, V. 133, No. 4, Part 2, pp. 157A, Abstract 174		
BW	Carpinito, et al., (1996) "Successful Adoptive Immunotherapy of Cancer Using In Vitro Immunized Autologous Lymphocytes and Cimetidine," Surgical Forum Vol. XXXVII, New Orleans		
BX	Carson et al. (1991) "Rat Mitogen-Stimulated Lymphokine-Activated T Killer Cells: Production and Effects on C6 Glioma Cells In Vitro and In Vivo in the Brain of Wistar Rats", Journal of Immunotherapy, 10: 131 -140		
BY	Casper et al., (1994) "Phase II trial of gemcitabine (2,2'difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas" Invest. New Drugs 12:29-34 (Abstract only)		
BZ	Cavallo et al., (1992) "Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene" J. Immunol. 149(11):3627-3635.		
CA	Chang et al., (1997) "Phase I clinical trial of allogeneic mixed lymphocyte culture (cytotoimplant) delivered by endoscopic ultrasound (EUS)-guided fine needle injection (FNI) in patients with advanced pancreatic carcinoma" Gastroenterology 112(4): A546.		
CB	Colombo et al., (1995) "Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials?" Cancer Immunol. Immunother. 41:265-270.		
CC	Current Protocols in Immunology, Volume I, J.E. Coligan et al., eds., John Wiley & Sons, Inc., Supplement 28, Table of Contents, pp. 1-9 (1998).		
CD	Current Protocols in Molecular Biology, Volume I, F.M. Ausubel et al., (1995) eds., John Wiley & Sons, Inc., Table of Contents, Supplement 30, 39-40, pp. iii-xii		

EXAMINER	DATE CONSIDERED
<i>Chris S. H.</i>	5/28/02
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED
 APR 02 2001
 USPTO
 100-2000

INFORMATION DISCLOSURE CITATION			ATTY. DOCKET NO.	SERIAL NO.
Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>			IRVN-005CIP	09/771,263
			APPLICANT	Thompson et al.
			FILING DATE	GROUP
			January 26, 2001	Unassigned
CY	CE	Damle et al., (1981) "Autologous Mixed Lymphocyte Reaction in Man. II. Histamine-Induced Suppression of the Autologous Mixed Lymphocyte Reaction by T-Cells Subsets Defined with Monoclonal Antibodies," J. Clin Immunol 1:241-249		
	CF	Davis et al., (1980) "Antibody Formation Hagerstown," Microbiology 3rd ed., Harper & Row Publishers, Inc., Ch. 19, pp.420-422		
	CG	DECLARATION BY GALE A. GRANGER regarding Human Clinical Trials		
	CH	DECLARATION BY JOHN C. HISERODT regarding Human Clinical Trials		
	CI	Declaration by Tetsuya Gatanaga Pursuant to 37 CFR § 1.56 Regarding Clinical Trial Conducted under IND-6288 (with Appendices A & B)		
	CJ	Dillman et al. (1993) "Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy." J. Immunother. Vol. 14:65-69		
	CK	Dranoff et al. (1993) "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity." Proc. Natl. Acad. Sci. USA, Vol. 90:3539-3543.		
	CL	Dugan et al., "Current concepts in pancreatic cancer. Symposium summary." (1998) Pancreas 17:325-33		
	CM	Eisenthal, A. et al., (1986) "The Effect of Cimetidine on PBL from Healthy Donors and Melanoma Patients: Augmentation of T Cell Responses to TCGF* Mitogens and Alloantigens and of TCGF Production," Cancer Immunol. Immunother. 27:141-147		
	CN	Finke et al., (1990) "Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma" Cancer Research 50:2363-2370.		
	CO	Fleshner et al., (1990) "Potential of allogeneic tumorcidal cytotoxic T lymphocytes in brain tumor adoptive immunotherapy" J. Cell. Biochem. Suppl. 0 (14 Part B) page 95 (Abstract CE407).		
	CP	Fletcher et al. (1987) "Recent Advances in the Understanding of the Biochemistry and Clinical Pharmacology of Interleukin-2", Lymphokine Research, 6:45-57.		
	CQ	Gastl et al . , (1992) "Retroviral Vector-mediated by Lymphokine Gene Transfer Into Human Renal Cancer Cells," Cancer Research 52:6229-6236		
	CR	Gately (1982) "In vitro studies on the cell-mediated immune response to human brain tumors. I. Requirement for third-party stimulator lymphocytes in the induction of cell-mediated cytotoxic responses to allogeneic cultured gliomas." J. Natl. Cancer. Inst., Vol. 19:1245-1254.		
	CS	Gifford et al., (1988) "Histamine Type-2 Receptor Antagonist Immune Modulation. I. Increased Cell-Mediated Cytotoxicity in normal and in Down-Regulated Systems," Surgery 103(2):184-192		
	CT	Giulivi et al., (1986) "Effects of Cimetidine on In Vitro Transformation of Peripheral Monocytes to Macrophages in Healthy Volunteers and Cancer Patients," Intl. J. Immunopharmacol. 5:517-523		
	CU	Gold et al., (1993) "Adoptive Chemoimmunotherapy for the Treatment of Relapsed and Refractory Solid Tumors Using Ex Vivo Activated Memory T Cells (Autolymphocyte Therapy) and Cyclophosphamide," J. Immunother. 73:213-221		
↓	CV	Gold et al., (1993) "Adoptive Chemoimmunotherapy Using Ex Vivo Activated Memory T Cells and Cyclophosphamide: Tumor Lysis Syndrome of a Metastatic Soft Tissue Sarcoma," Am. J. Hematol. 44:42-47		

EXAMINER	Christopher L Y	DATE CONSIDERED	5/28/02
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. IRVN-005CIP	SERIAL NO. 09/771,263
			APPLICANT Thompson et al.	
			FILING DATE January 26, 2001	GROUP Unassigned
CY	CW	Golumbek et al. (1992) "Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines." J. Immunother., Vol. 12:224-230		
	CX	Gordon et al., (1980) "Cell Mediated Immune Response and Cimetidine," The Michigan Academician pgs. 280-289		
	CY	Graham et al., (1993) "The Use of Ex Vivo- Activated Memory T Cells (Autolymphocyte Therapy) in the Treatment of Metastatic Renal Cell Carcinoma: Final Results From a Randomized, Controlled, Multisite Study," Sem. Urol. 11:27-34		
	CZ	Granger et al., (1995) "Basic and clinical studies of intralesional therapy of gliomas with allogeneic lymphoid cells" Proc. Amer. Assoc. Cancer Res. 36:472 (Abstract 2812).		
	DA	Hayes et al., (1988) "Recombinant interleukin-2-related intracerebral toxicity and LAK/rIL-2 therapy for brain tumors" Lymphokine Res. 2(3):337 (Abstract 9.25).		
	DB	Hidalgo et al., (1999) "Phase HI study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer." J. Clin. Oncol. 17:585-92.		
	DC	Jeffes III et al., (1991) "Therapy of recurrent high-grade gliomas with surgery, autologous mitogen-activated IL-2-stimulated (MAK) killer lymphocytes, and rIL-2: II. Correlation of survival with MAK cell tumor necrosis factor production in vitro" Lymphokine and Cytokine Research 10(2):89-94.		
	DD	Kondo et al. (1984) "Rationale for a Novel Immunotherapy of Cancer with Allogeneic Lymphocyte Infusion," Medical Hypotheses 15:241-277		
	DE	Kruse et al. (1990) "Analysis of Interleukin 2 and Various Effector Cell Populations in Adoptive Immunotherapy of 9L Rat Gliosarcoma; Allogeneic Cytotoxic T Lymphocytes Prevent Tumor Take," Proc. Natl. Acad. Sci. USA 87:9577-9581		
	DF	Kruse et al. (1996) "Immune Therapy of Recurrent Malignant Gliomas: Intracavitary Allogeneic Cytotoxic T Lymphocytes and Human Recombinant Interleukin-2," FASEB J. 10(6):A2387		
	DG	Kruse et al., (1997) "Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumour" Biotechnol. Appl. Biochem. 25:1-9.		
	DH	(Galley proof of article that was later published as Biotechnol. Appl. Biochem. (1997) 25(3): 197-205.)		
	DI	Kruse et al., (1997) "Cellular therapy of brain tumors: clinical trials" Advances in Neuro-Oncology II Futura Publishing Company, Chapter 22, pages 487-504.		
	DJ	Kruse et al., (1994) "Migration of activated lymphocytes when adoptively transferred into cannulated rat brain" J. Neuroimmunol. 55:11-21.		
	DK	Kruse et al., (1993) "Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma" J. Neuro-Oncology 15:97-112.		
	DL	Kruse et al., (1994) "Intracranial Administration of Single or Multiple Source Allogeneic Cytotoxic T Lymphocytes: Chronic Therapy for Primary Brain Tumors," J. Neurooncol. 19:161-168		
	DM	Kruse et al., (1995) "Development of Human Allogenic CTL in an Artificial Capillary System for Intracavitary Treatment of Malignant Glioma," Proc. Am. Assoc. Cancer Res. 36:474		
✓	DN	Lavin et al., (1992) "Autolymphocyte Therapy for Metastatic Renal Cell Carcinoma: Initial Clinical Results From 335 Patients Treated in a Multisite Clinical Practice," Transplant Proc. 24:3059-3064.		

EXAMINER <i>Christopher H. Yen</i>	DATE CONSIDERED <i>5/28/02</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED
APR 02 2001
REF ID: 602001

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>Please several sheets if necessary</i>		ATTY. DOCKET NO. IRVN-005CIP	SERIAL NO. 09/771,263
		APPLICANT Thompson et al.	
		FILING DATE January 26, 2001	GROUP Unassigned
CY	DO	Leshem et al., (1984) "In vitro elicitation of cytotoxic response against a nonimmunogenic murine tumor by allosensitization," <i>Cancer Immunology Immunotherapy</i> 17:117-123	
	DP	Lillehei et al. (1991) "Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy." <i>Neurosurgery</i> , Vol. 28:16-23.	
	DQ	Ioli et al., (1994) "Basic & clinical studies with intratumor immunotherapy of gliomas with allogeneic lymphoid cells" <i>Proc. Amer. Assoc. Cancer Res.</i> 35:518 (Abstract 3088).	
	DR	Marshall et al., (1989) "Effects of Coumarin (1,2-Benzopyrone) on Lymphocyte, Natural Killer Cell, and Monocyte Functions In Vitro," <i>J. Biol. Resp. Modifiers</i> 8: 70-85	
	DS	McCarty, M.F., (1985) "Addendum: Cimetidine as an Adjuvant for Allogeneic Lymphocyte Immunotherapy of Cancer" <i>Medical Hypotheses</i> 77:155-156	
	DT	Merchant et al . , (1988) "Adoptive Immunotherapy for Recurrent Glioblastoma Multiforme Using Lymphokine Activated Killer Cells and Recombinant Interleukin-2," <i>Cancer</i> 62:665-671	
	DU	Merchant et al., (1990) "Immunotherapy for Malignant Glioma Using Human Recombinant Interleukin-2 and Activated Autologous Lymphocytes . A Review of Pre-clinical and Clinical Investigations," <i>J. Neurooncol</i> . 8:173-188	
	DV	Methods in Enzymology, Volume LVIII, Cell Culture, W.B. Jakoby et al., eds., (1979) Academic Press, New York, Table of Contents, pp. v-viii	
	DW	Michael et al., (1997) "Clinical experience with gemcitabine in pancreatic carcinoma." <i>Oncology</i> 11:1615-25	
	DX	Miller, J.M. & Calos, M.P. eds., (1987) "Gene Transfer Vectors for Mammalian Cells" Table of Contents, pp. vii-ix	
	DY	Mitchell et al., (1993) "Active specific immunotherapy of melanoma with allogeneic cell lysates" <i>Ann. N.Y. Acad. Sci.</i> 690:153-166.	
	DZ	Molecular Cloning: A Laboratory Manual, Second Edition, J. Sambrook et al., eds., (1989) Cold Spring Harbor Laboratory Press, Table of Contents, pp. xi-xxxviii	
	EA	Naganuma et al., (1989) "Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells" <i>Acta. Neurochir.</i> 99:157-160.	
	EB	Oligonucleotide Synthesis: A Practical Approach, M.J. Gait, ed., (1984) IRL Press, Oxford, Table of Contents, pp. vii-xii	
	EC	Osband et al., (1990) "Effect of Autolympocyte Therapy on Survival and Quality of Life in Patients with Metastatic Renal-Cell Carcinoma," <i>Lancet</i> 335:994-998	
	ED	Osband et al., (1981) "Succesful Tumour Immunotherapy with Cimetidine in Mice," <i>Lancet</i> 1:636-638	
	EE	Osband, et al., (1986) "Improved Adoptive Cell Immunotherapy by Pre-Infusion Depletion of Suppressor Cells and In Vivo Suppressor Cell Blockade," <i>Proceedings of ASCO</i> , Vol. 5, pp. 232, Abstract 908	
	EF	Palacios, et al., (1980) "Cimetidine Abrogates Suppressor T Cell Function In Vitro," <i>Immunology Letters</i> , Vol. 3:33-37	
	EG	Pardoll, (1992) "New Strategies for Active Immunotherapy with Genetically Engineered Tumor Cells," <i>Current Opinion in Immunology</i> 4:619-623	
	EH	Penhaligon, et al. (1984) "Antimetastatic Effect of Cimetidine on Mice Bearing a C3H Mouse Mammary Adenocarcinoma: Survival and Lymphocyte Function Studies," <i>Clin. Exp. Metastasis</i> , Vol. 2, No. 1:37-5	

EXAMINER <i>Christopher Hyc</i>	DATE CONSIDERED <i>1/28/01</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. IRVN-005CIP	SERIAL NO. 09/771,263																																																																																																																			
			APPLICANT Thompson et al.																																																																																																																				
			FILING DATE January 26, 2001	GROUP Unassigned																																																																																																																			
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;">CY</td> <td style="width: 10%;">EI</td> <td colspan="3">Plaut et al., (1975) "Properties of a Subpopulation of T Cells Bearing Histamine Receptors," J. Clin. Invest. 55:856-874</td> </tr> <tr> <td></td> <td>EJ</td> <td colspan="3">Protocol 1 (item 1): Phase I trial for brain cancer, Good Samaritan Hospital. Protocol version originally filed with the IRB at the Good Samaritan Hospital.</td> </tr> <tr> <td></td> <td>EK</td> <td colspan="3">Protocol 1 (item 2): Phase I trial for brain cancer, Good Samaritan Hospital. Protocol version as subsequently amended to cover 20 patients.</td> </tr> <tr> <td></td> <td>EL</td> <td colspan="3">Protocol 1 (item 3): "Informed Consent Form" (Patient)</td> </tr> <tr> <td></td> <td>EM</td> <td colspan="3">Protocol 2 (item 1): Phase I trial for brain cancer, Long Beach Memorial Hospital</td> </tr> <tr> <td></td> <td>EN</td> <td colspan="3">Protocol 2 (item 2): "Consent to Act as a Research Subject" (Donor)</td> </tr> <tr> <td></td> <td>EO</td> <td colspan="3">Protocol 2 (item 3): "Consent to Act as a Research Subject" (Patient)</td> </tr> <tr> <td></td> <td>EP</td> <td colspan="3">Protocol 3 (item 1): Phase I trial for metastatic melanoma, U.C.I. Medical Center</td> </tr> <tr> <td></td> <td>EQ</td> <td colspan="3">Protocol 3 (item 2): "Consent to Act as a Human Research Subject" (Donor)</td> </tr> <tr> <td></td> <td>ER</td> <td colspan="3">Protocol 3 (item 3); "Consent to Act as a Human Research Subject" (Patient)</td> </tr> <tr> <td></td> <td>ES</td> <td colspan="3">Protocol 4 (item 1): Phase I trial for pancreatic cancer, U.C.I. Medical Center</td> </tr> <tr> <td></td> <td>ET</td> <td colspan="3">Protocol 4 (item 2): "Consent to Act as a Human Research Subject" (Patient)</td> </tr> <tr> <td></td> <td>EU</td> <td colspan="3">Protocol 4 (item 3): "Consent to Act as a Human Research Subject" (Donor)</td> </tr> <tr> <td></td> <td>EV</td> <td colspan="3">Protocol 5 (item 1): Phase I trial for bladder & prostate cancer, U.C.I. Medical Center</td> </tr> <tr> <td></td> <td>EW</td> <td colspan="3">Protocol 5 (item 2): "Consent to Act as a Human Research Subject" (Patient)</td> </tr> <tr> <td></td> <td>EX</td> <td colspan="3">Protocol 5 (item 3): "Consent to Act as a Human Research Subject" (Donor)</td> </tr> <tr> <td></td> <td>EY</td> <td colspan="3">Protocol 6: Phase II trial for brain cancer, Good Samaritan Hospital</td> </tr> <tr> <td></td> <td>EZ</td> <td colspan="3">Protocol 7: Phase II trial for brain cancer, U.C.I. Medical Center</td> </tr> <tr> <td></td> <td>FA</td> <td colspan="3">Protocol for Phase I study at Hospital of the Good Samaritan, "A Phase I study to establish the effects of intratumor implants of allogeneic peripheral blood mononuclear cells (PBM), sensitized against patient alloantigens by MLC, in patients with recurrent glioblastoma" Principal Investigators: Deane Jacques, M.D. and Gale A. Granger, Ph.D..</td> </tr> <tr> <td></td> <td>FB</td> <td colspan="3">Redd et al., (1992) "Allogeneic Tumor-specific Cytotoxic T Lymphocytes," Cancer Immunol. Immunother. 34:349-354</td> </tr> <tr> <td></td> <td>FC</td> <td colspan="3">Remington's Pharmaceutical Sciences, 18th Edition, A.R. Gennaro, ed., (1990) Mack Publishing Co., Easton, PA, Table of Contents, pp. xv-xvi</td> </tr> <tr> <td></td> <td>FD</td> <td colspan="3">Richtsmeier et al., (1987) "Selective, Histamine-Mediated Immunosuppression in Laryngeal Cancer," Ann. Otol. Rhinol. Laryngol. 96:569-572</td> </tr> <tr> <td></td> <td>FE</td> <td colspan="3">Rosenberg et al., (1990) "Gene Transfer into Humans – Immunotherapy of Patients with Advanced Melanoma, Using Tumor-infiltrating Lymphocytes Modified by Retroviral Gene Transduction," New England Journal of Medicine 323:570-578</td> </tr> </table>					CY	EI	Plaut et al., (1975) "Properties of a Subpopulation of T Cells Bearing Histamine Receptors," J. Clin. Invest. 55:856-874				EJ	Protocol 1 (item 1): Phase I trial for brain cancer, Good Samaritan Hospital. Protocol version originally filed with the IRB at the Good Samaritan Hospital.				EK	Protocol 1 (item 2): Phase I trial for brain cancer, Good Samaritan Hospital. Protocol version as subsequently amended to cover 20 patients.				EL	Protocol 1 (item 3): "Informed Consent Form" (Patient)				EM	Protocol 2 (item 1): Phase I trial for brain cancer, Long Beach Memorial Hospital				EN	Protocol 2 (item 2): "Consent to Act as a Research Subject" (Donor)				EO	Protocol 2 (item 3): "Consent to Act as a Research Subject" (Patient)				EP	Protocol 3 (item 1): Phase I trial for metastatic melanoma, U.C.I. Medical Center				EQ	Protocol 3 (item 2): "Consent to Act as a Human Research Subject" (Donor)				ER	Protocol 3 (item 3); "Consent to Act as a Human Research Subject" (Patient)				ES	Protocol 4 (item 1): Phase I trial for pancreatic cancer, U.C.I. Medical Center				ET	Protocol 4 (item 2): "Consent to Act as a Human Research Subject" (Patient)				EU	Protocol 4 (item 3): "Consent to Act as a Human Research Subject" (Donor)				EV	Protocol 5 (item 1): Phase I trial for bladder & prostate cancer, U.C.I. Medical Center				EW	Protocol 5 (item 2): "Consent to Act as a Human Research Subject" (Patient)				EX	Protocol 5 (item 3): "Consent to Act as a Human Research Subject" (Donor)				EY	Protocol 6: Phase II trial for brain cancer, Good Samaritan Hospital				EZ	Protocol 7: Phase II trial for brain cancer, U.C.I. Medical Center				FA	Protocol for Phase I study at Hospital of the Good Samaritan, "A Phase I study to establish the effects of intratumor implants of allogeneic peripheral blood mononuclear cells (PBM), sensitized against patient alloantigens by MLC, in patients with recurrent glioblastoma" Principal Investigators: Deane Jacques, M.D. and Gale A. Granger, Ph.D..				FB	Redd et al., (1992) "Allogeneic Tumor-specific Cytotoxic T Lymphocytes," Cancer Immunol. Immunother. 34:349-354				FC	Remington's Pharmaceutical Sciences, 18 th Edition, A.R. Gennaro, ed., (1990) Mack Publishing Co., Easton, PA, Table of Contents, pp. xv-xvi				FD	Richtsmeier et al., (1987) "Selective, Histamine-Mediated Immunosuppression in Laryngeal Cancer," Ann. Otol. Rhinol. Laryngol. 96:569-572				FE	Rosenberg et al., (1990) "Gene Transfer into Humans – Immunotherapy of Patients with Advanced Melanoma, Using Tumor-infiltrating Lymphocytes Modified by Retroviral Gene Transduction," New England Journal of Medicine 323:570-578		
CY	EI	Plaut et al., (1975) "Properties of a Subpopulation of T Cells Bearing Histamine Receptors," J. Clin. Invest. 55:856-874																																																																																																																					
	EJ	Protocol 1 (item 1): Phase I trial for brain cancer, Good Samaritan Hospital. Protocol version originally filed with the IRB at the Good Samaritan Hospital.																																																																																																																					
	EK	Protocol 1 (item 2): Phase I trial for brain cancer, Good Samaritan Hospital. Protocol version as subsequently amended to cover 20 patients.																																																																																																																					
	EL	Protocol 1 (item 3): "Informed Consent Form" (Patient)																																																																																																																					
	EM	Protocol 2 (item 1): Phase I trial for brain cancer, Long Beach Memorial Hospital																																																																																																																					
	EN	Protocol 2 (item 2): "Consent to Act as a Research Subject" (Donor)																																																																																																																					
	EO	Protocol 2 (item 3): "Consent to Act as a Research Subject" (Patient)																																																																																																																					
	EP	Protocol 3 (item 1): Phase I trial for metastatic melanoma, U.C.I. Medical Center																																																																																																																					
	EQ	Protocol 3 (item 2): "Consent to Act as a Human Research Subject" (Donor)																																																																																																																					
	ER	Protocol 3 (item 3); "Consent to Act as a Human Research Subject" (Patient)																																																																																																																					
	ES	Protocol 4 (item 1): Phase I trial for pancreatic cancer, U.C.I. Medical Center																																																																																																																					
	ET	Protocol 4 (item 2): "Consent to Act as a Human Research Subject" (Patient)																																																																																																																					
	EU	Protocol 4 (item 3): "Consent to Act as a Human Research Subject" (Donor)																																																																																																																					
	EV	Protocol 5 (item 1): Phase I trial for bladder & prostate cancer, U.C.I. Medical Center																																																																																																																					
	EW	Protocol 5 (item 2): "Consent to Act as a Human Research Subject" (Patient)																																																																																																																					
	EX	Protocol 5 (item 3): "Consent to Act as a Human Research Subject" (Donor)																																																																																																																					
	EY	Protocol 6: Phase II trial for brain cancer, Good Samaritan Hospital																																																																																																																					
	EZ	Protocol 7: Phase II trial for brain cancer, U.C.I. Medical Center																																																																																																																					
	FA	Protocol for Phase I study at Hospital of the Good Samaritan, "A Phase I study to establish the effects of intratumor implants of allogeneic peripheral blood mononuclear cells (PBM), sensitized against patient alloantigens by MLC, in patients with recurrent glioblastoma" Principal Investigators: Deane Jacques, M.D. and Gale A. Granger, Ph.D..																																																																																																																					
	FB	Redd et al., (1992) "Allogeneic Tumor-specific Cytotoxic T Lymphocytes," Cancer Immunol. Immunother. 34:349-354																																																																																																																					
	FC	Remington's Pharmaceutical Sciences, 18 th Edition, A.R. Gennaro, ed., (1990) Mack Publishing Co., Easton, PA, Table of Contents, pp. xv-xvi																																																																																																																					
	FD	Richtsmeier et al., (1987) "Selective, Histamine-Mediated Immunosuppression in Laryngeal Cancer," Ann. Otol. Rhinol. Laryngol. 96:569-572																																																																																																																					
	FE	Rosenberg et al., (1990) "Gene Transfer into Humans – Immunotherapy of Patients with Advanced Melanoma, Using Tumor-infiltrating Lymphocytes Modified by Retroviral Gene Transduction," New England Journal of Medicine 323:570-578																																																																																																																					

EXAMINER

Christopher HX

DATE CONSIDERED

5/28/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
APR 02 2001
PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. IRVN-005CIP	SERIAL NO. 09/771,263
		APPLICANT Thompson et al.	
		FILING DATE January 26, 2001	GROUP Unassigned
CY	FF	Rosenberg et al . , (1987) "A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-activated Killer Cells and Interleukin-2 or high-dose interleukin-2 alone, " New England Journal of Medicine 316:889-897	
	FG	Rotherberg et al., (1996) "A phase 11 trial of gemcitabine in patients with 5-FU-refractory pancreas cancer." Ann. Oncol. 7:347-53	
	FH	Saito et al . , (1994) "Immunotherapy of Bladder Cancer with Cytokine Gene-Modified Tumor Vaccines," Cancer Research 54:3516-3520	
	FI	Santin et al. (1995) "Development and characterization of an IL-4 secreting human ovarian carcinoma cell line." Gynecol. Oncol., Vol. 58:230-239.	
	FJ	Santin et al. (1996) "Development and characterization of an interleukin-2-transduced human ovarian tumor vaccine not expressing major histocompatibility complex molecules." Am. J. Obst. Gynecol., Vol. 174: 633-639.	
	FK	Santin et al. (1995) "Development and in vitro characterization of a GM-CSF secreting human ovarian carcinoma tumor vaccine." Int. J. Gynecol. Cancer, Vol. 5:401-410.	
	FL	Schiltz et al., (1995) "Movement of allogeneic cytotoxic T lymphocytes (aCTL) infused into the parietal region of 9L gliosarcoma bearing brain" Proceedings of the American Association for Cancer Research 36:458 (Abstract 272)	
	FM	Schiltz et al., (1995) "Treatment of 9L gliosarcoma with interferon-gamma enhances its cytolysis by alloreactive cytotoxic T lymphocytes in vitro" FASEB J. 9(4):A1044 (Abstract 6052).	
	FN	Schirrmacher et al . , (1995) "Workshop: Active Specific Immunotherapy with Tumor Cell Vaccines," J. Cancer Res. Clin. Oncol. 121:487-489	
	FO	Stephens, (1998) "Gemcitabine: A new approach to treating pancreatic cancer." Oncol. Nurs. Forum 25:87-93	
	FP	Stomiolo et al., (1999) "An investigational new drug treatment program for patients with gemcitabine." Cancer 15: 1261-8.	
	FQ	Strausser et al . , (1981) "Lysis of Human Solid Tumors by Autologous Cells Sensitized In Vitro to Alloantigens," J. Immunol. 127:266-271	
	FR	Streilein, (1995) "Unraveling Immune Privilege" Science 270:1158-1159.	
	FS	The Polymerase Chain Reaction, K.B. Mullis et al., eds., (1994) Birkhauser, Boston, MA, Table of Contents, pp. xv-xvii	
	FT	Topalian et al., (1988) "Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study" J. Clinical Oncology 6(5):839-853.	
	FU	Vieweg et al . , (1994) "Immunotherapy of Prostate Cancer in the Dunning Rat Model: Use of Cytokine Gene Modified Tumor Vaccines," Cancer, Res. 54:1760-1765	
	FV	Weir's Handbook of Experimental Immunology, Fifth Edition, Volume I, Immunochemistry and Molecular Immunology, D.M. Weir et al., eds., (1996) Blackwell Science, Cambridge, MA, Table of Contents, pp. v-xii	
↓	FW	Yoshida et al., (1988) "Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors" Cancer Research 48:5011-5016.	

EXAMINER <i>Christopher H</i>	DATE CONSIDERED <i>5/28/01</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. IRVN-005CIP	SERIAL NO. 09/771,263
		APPLICANT Thompson et al.	
		FILING DATE January 26, 2001	GROUP Unassigned
APR 02 2001 CY	FX	Zarling et al., (1978) "Generation of Cytotoxic T Lymphocytes to Autologous Human Leukaemia Cells by Sensitisation to Pooled Allogeneic Normal Cells," Nature 274:269-271	
	FY	Zeltzer et al., (1995) "Brain tumor vaccines and artificial lymph nodes in brain tumors - fantasy or reality?" Med. Fed. Oncol. 25:277.	

F:\DOCUMENT\IRVN (UC Irvine)\005CIP\IDS 1449.doc

RECEIVED

APR 04 2001

TECH CENTER 1600/2900

EXAMINER <i>Christopher M X</i>	DATE CONSIDERED <i>5/28/02</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	